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Abstract 
The aim of this prospective study was to investigate whether Spinal Cord Stimulation (SCS) 
significantly reduces pain intensity up to 18-month follow up in patients with chronic 
neuropathic pain. Forty three patients were recruited from the Pain Management Clinic at 
Russells Hall Hospital, Dudley, England. Patients rated their pain using a Visual Analogue 
Scale (VAS) at baseline (one week prior to SCS surgery) and at six, 12 and 18-months 
follow-up. Pain intensity significantly decreased from baseline to all three time points (F 
(3,126) =13.624 p<0.001). The greatest difference in pain intensity reduction was observed 
between baseline (M=7.13, SD=1.30) and six-month follow-up (M=4.83, SD=2.14), 
t(42)=5.875, p<0.001. However, when looking at differences between six-month follow-up 
and subsequent assessments, statistically significant increases in pain intensity from six-
months to 12-months follow-up t(42)=-2.483, p=0.017 and from six-months to 18-months 
follow-up t(42)=-3.121, p=0.003 could be observed. Statistically significant changes were 
also observed for clinical changes in pain scores, F (2,84) =4.244 p=0.018. There was a 
significant decrease in the percentage of clinical change obtained from six (M=29.44, 
SD=35.2) to 12-months follow-up (M=20.59, SD=33.9), t(42)=2.057, p=0.046 and from six 
month to 18-months follow-up (M=14.34, SD=32.7), t(42)=2.889, p=0.006. A number of 
patients also reported higher levels of pain intensity at 12 and 18-month follow-up than at 
baseline. These findings suggest that the beneficial effect of SCS on pain intensity may 
diminish over time and that six-month follow up scores may reflect a placebo effect.  
 
Key Words: Chronic pain, Spinal Cord Stimulation, Clinical Efficacy, Neuropathic pain, 
attrition 
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1. Introduction 
Acute pain serves an important role in alerting the body to potential damage, in this way it 
can serve to protect from further injury. However there is no beneficial effect and no 
functional purpose in chronic neuropathic pain. The exact prevalence of neuropathic pain 
remains unclear, though studies have reported a prevalence rate of 8% for pain of 
predominantly neuropathic nature [1] and 7% for pain with neuropathic characteristics [2]. 
Satisfactory treatment outcomes have proved problematic to achieve [3]. An insurance 
database study found that health care charges were three times higher for patients with 
neuropathic pain disorders compared with matched controls,[4] demonstrating the impact 
this condition can have not only on the individual but also on healthcare services.  
Spinal cord stimulation (SCS) has been used for the management of chronic pain 
syndromes since 1967 [5]. The concept for this implantable pulse generator (IPG) as a 
neuromodulator of chronic pain derives from the Gate Control Theory of Pain [6]. SCS 
comprises of an IPG which is connected to a number of electrodes implanted in the spinal 
canal. Electric fields are created using a programmed anode-cathode array, resulting in 
stimulation of the dorsal column fibers [7]. It is hypothesised that stimulation of these fibers 
facilitates supra-spinal mechanisms, leading to a decrease in activity in the ascending pain 
pathway (spinothalamic tract) with an increase in activity in the descending antinociceptive 
pathway [8]. Whilst the direct mechanisms of SCS remain unknown, SCS has an effect  on 
certain anti-nociceptive neurotransmitters, notably GABA. 
SCS is an invasive and initially expensive therapy; therefore it is necessary that this 
treatment be efficacious in reducing pain. Randomised controlled trials (RCT) have 
demonstrated the efficacy of SCS at six-month follow-up for the management of chronic 
regional pain syndrome (CRPS)[9] and failed back surgery syndrome (FBSS) [10,11]. Whilst 
SCS appears to be successful in treating certain neuropathic pain conditions at a six-month 
follow-up, a loss of analgesia is commonly experienced between 12 and 24 months [12]. 
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The aim of the current research was to investigate the effectiveness of SCS in maintaining 
the initial (six-month) pain relief levels up to 18-months post implantation in patients with 
chronic neuropathic pain. 
 
2. Methods 
2.1 Participants 
Recruitment took place following assessment and referral for SCS by a multidisciplinary 
team consisting of a pain consultant, clinical psychologist, nurse and physiotherapist. Patient 
suitability for SCS was assessed according to National Institute for Health and Clinical 
Excellence (NICE) guideline TAG159 [13]. Prior to implantation a trial period took place 
which evaluated individual response to SCS. Using local anaesthesia, the electrodes were 
inserted percutaneously whilst the patient was awake to provide feedback regarding 
paraesthesia coverage of the targeted painful area. The trial period lasted approximately one 
week. If the patient reported less than 50% pain relief, the electrical parameters would be 
modified to try and improve pain relief. Patients who consistently reported ≥ 50% pain relief 
proceeded to full implantation of the IPG. An unsuccessful trial where a patient reported less 
than 50% pain relief would result in the leads being removed.  
All patients invited to participate in this study were over 18 years of age and gave written 
informed consent. All SCS patients are invited to a neuromodulation clinic every six months 
and the data were collected during these routine follow-up appointments. These follow-up 
appointments allow for reprogramming of the devices if the patients perceived a decrease of 
the effect, to verify the regularity of SCS use and to assess if revision surgery would be 
required. Ethical approval was granted by the National Research Ethics Service (NRES) 
committee West Midlands - South Birmingham (REC reference: 13/WM/0007).  
Fifty-eight consecutive patients were initially recruited to participate in the study. Seven of 
the participants (12.3%) had an unsuccessful trial period, where less than 50% pain 
reduction was achieved. In line with current recommendations the device was not implanted 
for these patients [13]. Two patients (3%) had their device removed after 12-months follow 
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up and before 18-months follow due to inadequate pain reduction. One patient reported no 
longer using the stimulator at 12-months follow up due to the device having no benefit on 
pain levels, though the device was still implanted. A total of 48 patients were included in the 
final analysis. 
 
2.2 Study procedure 
The study was explained, participants were given time to consider their participation and 
written informed consent was obtained from all participants. Baseline assessment took place 
one week prior to the SCS trial period at their routine pre-operative assessment. Using a 10 
cm horizontal visual analogue scale (VAS) ranging from 0 (no pain) to 10 (worst possible 
pain) the participants were asked to indicate on the scale where they thought their pain was 
for the average day. Assessments were performed at baseline (one week prior to SCS trial), 
six-months, 12-months and 18-months following SCS implantation. All data were collected 
during routine follow-up appointments.  
In addition to collecting pain intensity scores, clinical change scores were calculated using 
the VAS scores measured at baseline, six-months, 12-months and 18-months follow-up 
(clinical change = (VAS pre-treatment – VAS post-treatment) / (VAS pre-treatment) x 100 
[14]. In accordance with a consensus statement by Dworkin et al (2008) an improvement 
between 10-29% was considered as a minimally important clinical change, between 30-49% 
as a clinically moderate change and ≥50% as a substantial clinical change [15]. 
Function scores were collected using the Oswestry Disability Index (ODI). The ODI assesses 
the impact of pain interference on 10 daily living activities, with participants required to pick 
from one of six statements to reflect their ability to manage this activity. Each statement is 
scored from 0-5. ODI scores between 0-20% indicate minimal disability; 21-40% moderate 
disability; 41-60% severe disability; 61-80% crippled; and 81-100% indicate bed bound or 
exaggeration of symptoms [16].The ODI is considered a valid measure of condition-specific 
disability [16]. 
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2.3. Data Analysis 
Repeated-measures ANOVA were performed to investigate changes in pain intensity, 
clinical change and disability scores between all evaluable assessments. Mauchly’s test was 
used to verify the assumption of sphericity with any violation of the sphericity assumption 
resulting in the use of Greenhouse-Geisser estimate of sphericity. T-tests were performed to 
analyse differences between two time points. Data is reported as mean ± standard deviation 
(range). Statistical significance was judged at 5% level. Statistical tests were carried out with 
the IBM Statistical Package for the Social Sciences (SPSS) Software (version 21, SPSS 
Inc., Chicago, IL, USA). 
 
3. Results 
3.1 Changes in pain intensity 
Forty–eight patients (25 female and 23 male) were included in the analysis (Table 1).  
 
Table 1 Demographic Information
 
                                      N=48 
Gender 
Age in Years 
Duration of Pain in 
Years 
Diagnosis 
FBSS 
CRPS 
Other
a 
Topography 
Back 
Head/Neck 
Arm/Hand 
Buttock/Leg/Foot 
Multiple 
F(25); M(23) 
46.7±1.5 (27-65) 
9.1±1.1 (1.5-40) 
 
 
12 
18 
18 
 
5 
2 
4 
23 
14 
Mean±SEM (range) 
 
a
 Other diagnosis included pancreatitis,  
arachnoiditis, intercostobranchial and bilateral 
deep vein thrombosis 
 
Repeated-measures ANOVA were performed to investigate changes in pain intensity 
between baseline, six-months, 12-months and 18-months follow-ups. Statistically significant 
improvements were observed for pain as measured with the VAS, F (3,135) =16.264, 
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p<0.001 (figure 1). Participants mean pain intensity scores reduced from baseline to six-
month follow-up; however an increase in pain intensity was observed in subsequent 
assessments up to the 18-months follow-up post implantation. 
 
 
Figure 1. Mean pain intensity from baseline to 18-month follow up  
 
A mixed between-within subjects ANOVA was performed to investigate the impact of 
diagnosis (FBSS, CRPS, Other) on pain intensity, across the four time point (baseline, six-
months, 12-months and 18-months). There was no significant interaction between diagnosis 
and time point, nor was there a significant main effect of diagnosis (p = ). 
 
Paired samples t-tests were used to investigate changes in pain intensity between time 
points. Pain intensity significantly decreased from baseline to all three time points. The 
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greatest difference in pain intensity reduction was observed between baseline (M=7.20, 
SD=1.34) and six-month follow-up (M=4.60, SD=2.20), t(47)=6.741, p<0.001. Statistically 
significant decreases from baseline to 12-months follow-up (M=5.40, SD=2.31), t(47)=5.23, 
p<0.001 and to 18-months follow-up (M=5.81, SD=2.21), t(47)=4.06, p<0.001 were also 
identified. 
However, when looking at differences between six-month follow-up and subsequent 
assessments, statistically significant increases in pain intensity from six-months to 12-
months follow-up t(47)=-2.788, p=0.008 and from six-months to 18-months follow-up t(47)=-
3.339, p=0.002 could be observed. There were no statistically significant increases in pain 
intensity from 12-months to 18-months follow-up (p = ). 
 
3.2 Clinical change  
Patients demonstrated minimally important clinical changes from baseline to six, 12 and 18-
months follow-up (table 2).  
 
Table 2. Clinical change 
    Six-months (n=48) 12-months (n=48) 18-months (n=48) 
None (< 10%) 10  15 18 
Minimal (10-29%) 14 14 13 
Moderate (30-49%) 7 4 7 
Substantial (≥ 50%) 17  15 10 
 
At six-month follow-up 14 patients presented minimally important clinical changes, seven 
patients presented moderately important clinical changes and 17 presented substantial 
clinical changes. However for eight patients there was an increase in pain at six-month 
follow-up from baseline, in addition to two patients for which there was no change in pain 
from baseline. At 12-months follow-up 14 patients presented minimally important changes, 
four presented moderately important changes and 15 presented substantial clinical changes. 
Conversely at 12-months follow-up 10 patients’ demonstrated an increase in pain with three 
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patients’ reporting no change from baseline and a further two patients presenting less than 
10% clinical change. At 18-months follow-up the number of patients presenting minimally 
important changes decreased to 13, though the number of patients presenting moderately 
important clinical change rose to seven. The number of patients presenting substantial 
clinical changes decreased to 10. Moreover at 18-month follow-up 12 patients showed an 
increase in pain ratings again with five patients obtaining no change from baseline, and one 
patients presenting less than 10% clinical change. 
Repeated-measures ANOVA were performed to investigate changes in clinical change 
scores between six-month, 12-months and 18-months follow-ups. Statistically significant 
changes were observed for clinical changes in pain scores, F (2,94) =4.972 p=0.009 (figure 
2). 
 
Figure 2. Mean clinical change scores up to 18-months follow up 
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There was a significant decrease in the percentage of clinical change obtained from six 
(M=33.19, SD=35.63) to 12-months follow-up (M=23.76, SD=33.62), t(47)=2.347, p=0.025 
and from six month to 18-months follow-up (M=18.34, SD=33.51), t(47)=3.072, p=0.004. 
There was no statistically significant difference in clinical change scores from 12-months to 
18-months follow-up. 
A mixed between-within subjects ANOVA was performed to investigate the impact of 
diagnosis (FBSS, CRPS, Other) on clinical change scores, across the time points. There 
was no significant interaction between diagnosis and time point, nor was there a significant 
main effect of diagnosis (p = ). 
 
3.3 Pain Related Disability 
Repeated-measures ANOVA were performed to investigate changes in functional scores 
(ODI) between baseline, six-months, 12-months and 18-months follow-ups. Statistically 
significant improvements were observed for pain related disability as measured with the ODI, 
F (3,141) =5.010, p=0.002. As with VAS pain intensity and clinical change scores, 
participant’s pain related disability scores reduced from baseline to six-month follow-up; 
however an increase in participants pain related disability scores was observed in 
subsequent assessments up to the 18-months follow-up post implantation. 
 
Paired samples t-tests were used to investigate changes in pain related disability scores 
between time points. Pain related disability scores significantly decreased from baseline 
(M=55.04, SD=16.43) to six-month follow up (M=46.98, SD=19.05), t(47)=3.464, p=0.001 
and from baseline to 12-month follow up (M=48.49, SD=20.94), t(47)= 2.918, p=0.005, but 
not 18-month follow up (M=51.75, SD=20.92), t(47)=1.330, p=.190. There was no significant 
change in pain related disability scores between six and 12-month follow up (p = ), though 
there was a significant increase in pain related disability between six and 18-month follow up 
t(47)=-2.188. p=0.034. There was no significant change in pain related disability scores 
between 12-month and 18-month follow up (p = ).  
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4. Discussion 
Our findings demonstrate that SCS can effectively reduce pain intensity from baseline up to 
18-months follow-up and can also result in important clinical changes being obtained up to 
18-months following SCS implantation. In addition to reducing pain intensity, our findings 
demonstrate that SCS can effectively reduce the interference of pain on the ability to carry 
out daily activities, however by 18-month follow this improvement in functionality ceases to 
be statistically significant. Using the VAS we observed that pain intensity significantly 
decreased from baseline to all three time points, with reported pain intensity being at its 
lowest at the six-month follow-up. However, this initial pain relief at six-month follow-up failed 
to be maintained with reported pain intensity increasing significantly from six-month follow-up 
to both 12 and 18-month follow-up. The VAS has been found to be both reliable and valid in 
measuring subjective phenomena including pain within the chronic pain population [17,18]. A 
systematic review identified the VAS as the most frequently used tool for assessing pain 
intensity [19]. 
In addition to this, the level of clinical change also significantly reduced from six-month 
follow-up to ensuing follow-ups. The proportion of patients who reported an increase in pain 
intensity increased at each time point, with eight more patients reporting a greater level of 
pain intensity at six-month follow up than at baseline, despite a ‘successful’ trial period. Two 
additional patients reported the same increase at 12-month follow up and another two 
additional patients reported the same increase in pain at 18-month follow up.  
The number of patients obtaining ≥50% clinical change reduced from 17 (35%) at six-month 
follow-up to 10 (21%) at 18-month follow-up. Similarly, whilst patients showed a significant 
decrease in pain related disability scores from baseline to six-month follow up and from 
baseline to 12-month follow up, from six month follow up pain related disability scores began 
to increase and by 18-month follow up there was no significant difference in pain related 
disability scores from baseline to 18-month follow up. These results suggest that a follow-up 
at six-months may not be an appropriate indicator as to how much pain relief and functional 
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improvement SCS will provide in the longer term and also that efficacy may begin to 
significantly decrease very early on into the treatment (prior to 12-months). These findings 
are in line with previous research which has found initial success of SCS in reducing pain at 
six-month follow up, but an inability to maintain this initial efficacy [9-11,20,21]. No 
differences in pain relief were observed between patients with a diagnosis of CRPS, FBSS 
or other. The interpretation of the subgroup analysis in this study is limited by the small 
number of patients per diagnosis. Future studies should take into consideration the degree 
of clinical change and rate of attrition per diagnosis (e.g. CRPS versus FBSS). 
A RCT involving patients with CRPS found that when compared to physiotherapy alone, 
SCS plus physiotherapy resulted in a significantly greater reduction in pain as measured by 
the VAS at six-month follow-up [9]. Despite this early indication of efficacy, a five-year follow-
up analysis concluded that the beneficial effects of SCS in reducing pain in patients with 
CRPS diminished over time [20]. At three year follow up there were no significant differences 
between the two groups, supporting our findings that SCS efficacy may start to decrease 
significantly after six to 12 months of treatment. Kumar and colleagues compared SCS with 
conventional medical management (CMM) in an RTC involving patients with FBSS with 
predominant leg pain or neuropathic origin [10]. At six-month follow-up, 24 SCS patients 
(48%) achieved 50% or more pain relief in the legs versus four CMM patients (9%). A follow-
up analysis at 24-months found the number of patients achieving 50% or more pain relief in 
the legs decreased to 37% in the SCS group and 2% in the CMM group, demonstrating a 
decrease in SCS efficacy from six-month follow-up onwards [21]. Whilst the current findings 
support previous research which has shown an inability to maintain the initial high levels of 
pain relief provided by SCS at six-month follow up, the current research suggests that this 
decrease in efficacy, at least in some patients may start earlier than previously suggested by 
Kemler and colleagues in their five-year follow-up study which concluded that the 
effectiveness of SCS lasted between two to three years. 
The initial success of SCS at reducing pain at six-month follow-up may be related to some 
placebo effects. It is likely that patients will initially have high expectations that the treatment 
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will reduce their pain. These expectations are likely to be heightened due to the high cost of 
the device and the invasive nature of the procedure leading the patient to view their pain 
more positively. The possibility to switch the device on and off using a remote has the 
potential to make the patients feel like they have more control over their pain. Expectations 
have been found to interact with the effectiveness of treatments [22]. This initial effect may 
also be linked to the additional social support received in the initial months following SCS 
implantation whilst the patient is adjusting to the device. Research investigating the role of 
perceived social support in explaining pain adjustment among chronic pain patients found 
that higher levels of social support resulted in decreases in pain intensity, which in turn 
decreased functional impairment [23]. This social support may decrease once the novelty of 
the device declines, resulting in an increase in pain intensity. It may be beneficial that 
patients are informed about this potential reduction in pain relief after the first six-months. 
This additional information may help the patients to cope better with the possible decrease in 
pain reduction in turn reducing the overall effect of this loss of analgesia. It can also be 
hypothesised that unspecified working mechanisms of SCS may not function indefinitely 
leading to an increase in pain as suggested by previous research [20,24-26]. 
Several hypotheses can be advanced to attempt to explain this decline in efficacy after six-
months of SCS. Studies investigating predictors of SCS outcome have identified a number of 
possible predictive variables; however discrepancies about some of the findings limit the 
possibility of a consensual agreement regarding which factors may be predictive of SCS 
outcome. Previously, operational factors (e.g. lead positioning, electrical parameters and 
complications) have been speculated to be the cause of this loss in analgesia, however this 
has also been observed in patients with no operational complications, suggesting that other 
factors may play a role [27]. More recently psychological factors have been hypothesised as 
impacting on SCS efficacy, though a recent systematic review concluded that there were no 
consistent psychological predictors of SCS outcomes [28]. This review also found that 
depression, previously identified as being a predictor of SCS outcome may actually improve 
as a result of SCS questioning its predictive value [28,29].  A further systematic review found 
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that older age and longer pain duration were predictive of poorer outcome in some studies 
[27]. Future prospective research is warranted to attempt to identify predictors of long-term 
outcome for patients being considered for SCS. 
One of the main strengths of this study is the regular follow-up allowing for detection of small 
changes. Previous research investigated SCS at larger incremental time points, often at six, 
12 and then 24-month follow-up. Furthermore previous studies have looked at pain intensity 
only, as opposed to also looking at clinical change and pain related disability. 
This study would benefit from studying patients over a longer period of time to identify 
whether efficacy stabilises or continues to progressively decrease. A limitation of this study 
would be the potential for assessment bias. However, all patients were given the 
questionnaires by a third party researcher not involved in the clinical management and 
completed them at their own discretion away from the pain management team, therefore 
reducing the risk of such bias. Other limitations include the limited number of patients and 
being a single centre study. Moreover the current research did not investigate concurrent 
analgesia use, a potential confounding variable. 
 
In conclusion, this study observed that SCS is effective for the management of chronic 
neuropathic pain; although the initial pain relief experienced significantly decreased six-
months following SCS implantation. A six-month assessment of pain reduction may not be 
indicative of long-term effectiveness as there may be too many placebo effects affecting pain 
perception at this time point. Some patients may actually experience an increase in pain 
intensity prior to 12-months following SCS implantation. 
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